Gregoire A J, Kumar R, Everitt B, Henderson A F, Studd J W
Mental Health Services, Salisbury Health Care, Salisbury, UK.
Lancet. 1996 Apr 6;347(9006):930-3. doi: 10.1016/s0140-6736(96)91414-2.
Postnatal depression can have long-term adverse consequences for the mother, for the marital relationship, and for the infant's psychological development. Such depressions can be severe and resistant to both support and counselling and to therapy with antidepressant drugs. We investigated the antidepressant efficacy of oestrogen given transdermally.
In a double-blind, placebo-controlled study, 61 women with major depression, which began within 3 months of childbirth and persisted for up to 18 months postnatally, were allocated randomly active treatment (n=34; 3 months of transdermal 17 beta-oestradiol 200 micrograms daily alone, then 3 months with added cyclical dydrogesterone 10mg daily for 12 days each month) or placebo (n=27; placebo patches and tablets according to the same regimen). The women were assessed monthly by self-ratings of depressive symptoms on the Edinburgh postnatal depression scale (EPDS) and by clinical psychiatric interview (schedule for affective disorders and schizophrenia [SADS]-change scale).
On pretreatment assessments the women in both groups were severely depressed (mean EPDS score 21.8 [SD 3.0] active group, 21.3 [2.9] placebo group; SADS scores, 66.3 [11.4] and 64.3 [10.7]). During the first month of therapy the women receiving oestrogen improved rapidly, and to a significantly greater extent than controls (mean EPDS scores 13.3 [SD 5.7] vs 16.5 [5.3]. Patients receiving placebo also improved over time but, on average, their scores did not fall below the screening threshold for major depression for at least 4 months. The estimated overall treatment effect of oestrogen on the EPDS was 4.38 points (95% Cl 1.89-6.87). None of a range of other factors (age, psychiatric, obstetric and gynaecological history, severity and duration of current episode of depression, and concurrent antidepressant medication), influenced the response to oestrogen.
This study has shown that transdermal oestrogen is an effective treatment for postnatal depression. Further studies are required to establish the minimum effective dose and shortest necessary duration of treatment as well as the mechanism of antidepressant action of oestrogen.
产后抑郁症会对母亲、婚姻关系以及婴儿的心理发育产生长期不良后果。此类抑郁症可能较为严重,对支持、咨询以及抗抑郁药物治疗均有抵抗性。我们研究了经皮给予雌激素的抗抑郁疗效。
在一项双盲、安慰剂对照研究中,61名产后3个月内起病且产后持续长达18个月的重度抑郁症女性被随机分配接受活性治疗(n = 34;先单独每日经皮给予17β - 雌二醇200微克,共3个月,然后加用周期性地屈孕酮,每日10毫克,每月服用12天,共3个月)或安慰剂(n = 27;按照相同方案给予安慰剂贴片和片剂)。通过爱丁堡产后抑郁量表(EPDS)对抑郁症状进行自我评分以及通过临床精神科访谈(情感障碍和精神分裂症评定量表[SADS] - 变化量表),每月对这些女性进行评估。
在治疗前评估中,两组女性均重度抑郁(活性组EPDS平均得分21.8[标准差3.0],安慰剂组21.3[2.9];SADS得分分别为66.3[11.4]和64.3[10.7])。在治疗的第一个月,接受雌激素治疗的女性改善迅速,且改善程度显著大于对照组(EPDS平均得分13.3[标准差5.7]对16.5[5.3])。接受安慰剂治疗的患者随时间也有所改善,但平均而言,其得分至少4个月未降至重度抑郁症的筛查阈值以下。雌激素对EPDS的总体估计治疗效果为4.38分(95%可信区间1.89 - 6.87)。一系列其他因素(年龄、精神病史、产科和妇科病史、当前抑郁发作的严重程度和持续时间以及同时服用的抗抑郁药物)均未影响对雌激素的反应。
本研究表明经皮雌激素是产后抑郁症的有效治疗方法。需要进一步研究以确定最低有效剂量、最短必要治疗时间以及雌激素的抗抑郁作用机制。